Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database
J.‐M. L'Orphelin(Centre Hospitalier Universitaire de Caen Normandie), Brigitte Dréno(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), S. Dalac‐Rat(Centre Hospitalier du Mans), A. Dupuy(Hôpital Pontchaillou), A. Dompmartin(Normandie Université), E. Maubec(Délégation Paris 7), Sara Le Naour(Centre Hospitalier Universitaire de Nantes), Mona Amini‐Adlé(Centre Léon Bérard), Émilie Varey(Inserm), F. Skowron, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), H. Montaudié(Centre Hospitalier Universitaire de Nice), Amir Khammari(Inserm), Nicolás Meyer(Université Toulouse III - Paul Sabatier), C. Lesage(Université de Montpellier), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, P. Celérier(Roche (France))
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k